medigraphic.com
ENGLISH

Revista de Investigación Clínica

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
  • Mostrar índice
  • Números disponibles
  • Información
    • Información general        
    • Directorio
  • Publicar
    • Instrucciones para autores        
  • medigraphic.com
    • Inicio
    • Índice de revistas            
    • Registro / Acceso
  • Mi perfil

2017, Número 6

<< Anterior Siguiente >>

Rev Invest Clin 2017; 69 (6)


Two-hundred Years Later: Is Parkinson’s Disease a Single Defined Entity?

Rodríguez-Violante M, Cervantes-Arriaga A, Fahn S, Tolosa E
Texto completo Cómo citar este artículo

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas: 308-313
Archivo PDF: 89.40 Kb.


PALABRAS CLAVE

Sin palabras Clave

RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lewy FH. Paralysis agitans: Pathologische anatomie. Handbuch der Neurologie. Vol. 3. Berlin: Springer; 1912. p. 920-33.

  2. Montagu KA. Catechol compounds in rat tissues and in brains of different animals. Nature. 1957;180:244-5.

  3. Carlsson A, Lindqvist M, Magnusson T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957;180:1200.

  4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045-7.

  5. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synclines from human brain. FEBS Lett. 1994;345:27-32.

  6. Marsden CD. Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1994;57:672-81.

  7. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386: 896-912.

  8. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord. 2014;29:454-62.

  9. Kell DB, Oliver SG. Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis- driven science in the post-genomic era. Bioessays. 2004; 26:99-105.

  10. Marras C, Lang A. Parkinson’s disease subtypes: Lost in translation? J Neurol Neurosurg Psychiatry. 2013;84:409-15.

  11. Marras C. Subtypes of Parkinson’s disease: State of the field and future directions. Curr Opin Neurol. 2015;28:382-6.

  12. van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J. The identification of Parkinson’s disease subtypes using cluster analysis: A systematic review. Mov Disord. 2010; 25:969-78.

  13. Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson’s disease: Clinical and prognostic implications. Neurology. 1985;35:522-6.

  14. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson’s disease: A base-line analysis of the DATATOP cohort. The Parkinson study group. Neurology. 1990;40: 1529-34.

  15. van der Heeden JF, Marinus J, Martinez-Martin P, Rodriguez- Blazquez C, Geraedts VJ, van Hilten JJ. Postural instability and gait are associated with severity and prognosis of Parkinson disease. Neurology. 2016;86:2243-50.

  16. Burn DJ, Rowan EN, Allan LM, Molloy S, O Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77:585-9.

  17. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71:499-504.

  18. Nagae LM, Honce JM, Tanabe J, Shelton E, Sillau SH, Berman BD. Microstructural changes within the basal ganglia differ between Parkinson disease subtypes. Front Neuroanat. 2016;10:17.

  19. Vervoort G, Alaerts K, Bengevoord A, et al. Functional connectivity alterations in the motor and fronto-parietal network relate to behavioral heterogeneity in Parkinson’s disease. Parkinsonism Relat Disord. 2016;24:48-55.

  20. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: A 39-year clinic pathologic study. Neurology. 2009;73:206-12.

  21. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society-unified Parkinson’s disease rating scale: Comparison with the unified Parkinson’s disease rating scale. Mov Disord. 2013;28: 668-70.

  22. Simuni T, Caspell-Garcia C, Coffey C, et al. How stable are Parkinson’s disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord. 2016;28:62-7.

  23. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21:1123-30.

  24. Nutt JG. Motor subtype in Parkinson’s disease: Different disorders or different stages of disease? Mov Disord. 2016; 31:957-61.

  25. Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22 Suppl 1:S41-6.

  26. van Rooden SM, Visser M, Verbaan D, Marinus J, van Hilten JJ. Patterns of motor and non-motor features in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80:846-50.

  27. Erro R, Picillo M, Vitale C, et al. Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism Relat Disord. 2016;28:137-40.

  28. van Rooden SM, Colas F, Martínez-Martín P, et al. Clinical subtypes of Parkinson’s disease. Mov Disord. 2011;26:51-8.

  29. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: A prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72:863-73.

  30. Marras C, Chaudhuri KR. Nonmotor features of Parkinson’s disease subtypes. Mov Disord. 2016;31:1095-2.

  31. Lawton M, Baig F, Rolinski M, et al. Parkinson’s disease subtypes in the oxford Parkinson disease centre (OPDC) discovery cohort. J Parkinsons Dis 2015;5:269-79.

  32. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: Clinical and pathologic study in a family. Neurology. 1994;44:437-1.

  33. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601-7.

  34. Kumaran R, Cookson MR. Pathways to Parkinsonism Redux: Convergent path biological mechanisms in genetics of Parkinson’s disease. Hum Mol Genet. 2015;24:R32-44.

  35. Lin MK, Farrer MJ. Genetics and genomics of Parkinson’s disease. Genome Med. 2014;6:48.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Invest Clin. 2017;69

ARTíCULOS SIMILARES

CARGANDO ...